Observation of Metabolic Changes in Chronic Schizophrenia After Neuroleptic Treatment by In Vivo Hydrogen Magnetic Resonance Spectroscopy

Choe, Bo-Young; Suh, T; Shinn, Kyung Sub; Lee, Chang-Wook; Lee, Chul; Paik, In‐Ho

doi:10.1097/00004424-199606000-00006

Cited by 80 publications

(78 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the Cho/Cr values showed difference with a p value of 0.03. The ratios computed with the RBFNN also compared favorably with those reported in literature [41][42][43][44][45]. The slight variations in the area ratios between published and our (RBFNN and LF) values are expected, since our values are averaged over all voxels covering different brain tissue types within the VOI whereas the published values are based on single voxel measurements.…”

Section: Human Brain Data-supporting

confidence: 78%

See 1 more Smart Citation

Fast quantification of proton magnetic resonance spectroscopic imaging with artificial neural networks

Bhat

Sajja

Narayana

2006

Journal of Magnetic Resonance

View full text Add to dashboard Cite

Accurate quantification of the MRSI-observed regional distribution of metabolites involves relatively long processing times. This is particularly true in dealing with large amount of data that is typically acquired in multi-center clinical studies. To significantly shorten the processing time, an artificial neural network (ANN) based approach was explored for quantifying the phase corrected (as opposed to magnitude) spectra. Specifically, in these studies radial basis function neural network (RBFNN) was used. This method was tested on simulated and normal human brain data acquired at 3T. The N-acetyl aspartate (NAA)/ creatine (Cr), choline (Cho)/Cr, Glutamate + Glutamine (Glx)/Cr, and Myo-inositol (mI)/Cr ratios in normal subjects were compared with the line fitting (LF) technique and jMRUI-AMARES analysis, and published values. The average NAA/Cr, Cho/Cr, Glx/Cr and mI/Cr ratios in normal controls were found to be 1.58 ± 0.13, 0.9 ± 0.08, 0.7 ± 0.17 and 0.42 ± 0.07 respectively. The corresponding ratios using the LF and jMRUI-AMARES methods were 1.6 ± 0.11, 0.95 ± 0.08, 0.78 ± 0.18, 0.49 ± 0.1 and 1.61 ± 0.15, 0.78 ± 0.07, 0.61 ± 0.18, 0.42 ± 0.13 respectively. These results agree with those published in literature. Bland-Altman analysis indicated an excellent agreement and minimal bias between the results obtained with RBFNN and other methods. The computational time for the current method was 15 seconds compared to approximately 10 minutes for the LF-based analysis.

show abstract

Section: Human Brain Data-supporting

confidence: 78%

“…The mI/Cr ratio obtained by the current analysis (RBFNN and LF) is slightly lower than that reported in literature [42][43][44]. This could be because the mI peak at 3.52 ppm is close to the water peak and the water suppression has a great effect on the quantitative values.…”

Section: Human Brain Data-contrasting

confidence: 77%

Fast quantification of proton magnetic resonance spectroscopic imaging with artificial neural networks

Bhat

Sajja

Narayana

2006

Journal of Magnetic Resonance

View full text Add to dashboard Cite

show abstract

“…Choe et al (1996) found low frontal NAA/Cre at baseline with no further reductions after naturalistic treatment with typical and atypical agents (follow-up 1-6 months). Fannon et al (2003) reported reduced medial temporal NAA/Cre at baseline which was no longer statistically different from healthy subjects after 3 months of atypical antipsychotic treatment.…”

Section: Discussionmentioning

confidence: 81%

“…Of these, Choe et al (1996) found no changes in NAA with treatment, whereas Fannon et al (2003) found evidence that atypical antipsychotic treatment was associated with an increase in NAA. Our preliminary report (10 schizophrenia patients from the current sample) suggested NAA reductions with antipsychotic treatment (Bustillo et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Proton Magnetic Resonance Spectroscopy During Initial Treatment With Antipsychotic Medication in Schizophrenia

Bustillo

Rowland

Jung

et al. 2007

Neuropsychopharmacol

View full text Add to dashboard Cite

Reduced brain N-acetyl-aspartate (NAA) has been repeatedly found in chronic schizophrenia and suggests neuronal loss or dysfunction. However, the potential confounding effect of antipsychotic drugs on NAA has not been resolved. We studied 32 minimally treated schizophrenia patients and 21 healthy subjects with single-voxel proton magnetic resonance spectroscopy ( 1 H-MRS) of the frontal and occipital lobes, caudate nucleus, and cerebellum. Concentrations of NAA, Choline, and Cre were determined and corrected for the proportion of cerebrospinal fluid (CSF) in the voxel. Patients were treated in a randomized-controlled double-blind manner with either haloperidol or quetiapine. 1 H-MRS was repeated every 6 months for up to 2 years. There was a group main effect for baseline NAA with lower global NAA in schizophrenia subjects before treatment compared to healthy controls. Global NAA was directly related to measures of global cognitive performance in the whole subject sample. Following treatment with haloperidol or quetiapine, there were no changes in NAA in any of the regions studied. Early in the illness, schizophrenia patients already demonstrate subtle reductions in NAA. Treatment with typical or atypical antipsychotic medications for several months does not result in NAA changes.

show abstract

“…Alterations in the levels of glutamate or glutamine could indicate abnormal neurotransmission or altered glial function. The hypothesis that alterations in glutamate and GABA neurotransmission might be corrected with treatments has begun to be evaluated with MRS (71)(72)(73), but a thorough exploration remains to be done. Since some recent novel pharmacotherapies proposed for schizophrenia, glutamate release inhibitors and selective agonists for the GABA A receptors bearing the a2 subunit, directly influence glutamatergic and GABA function (63,74), it is likely that a potential role for MRS in drug development for schizophrenia will receive careful study.…”

Section: Glutamate Glutamine and Gabamentioning

confidence: 99%

MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases

Mason

Krystal

2006

NMR Biomed.

View full text Add to dashboard Cite

Magnetic resonance spectroscopy (MRS) is likely in the near future to play a key role in the process of drug discovery and evaluation. As the pharmaceutical industry seeks biochemical markers of drug delivery, efficacy and toxicity, this non-invasive technique offers numerous ways to study adults and children repeatedly and without ionizing radiation. In this article, we survey an array of the information that MRS offers about neurochemistry in general and psychiatric disorders and their treatment in particular. We also present growing evidence of glial abnormalities in neuropsychiatric disorders and discuss what MRS is contributing to that line of investigation. The third major direction of this article is the discussion of where MRS techniques are headed and how those new techniques can contribute to studies of mechanisms of psychiatric disease and drug discovery.

show abstract

Observation of Metabolic Changes in Chronic Schizophrenia After Neuroleptic Treatment by In Vivo Hydrogen Magnetic Resonance Spectroscopy

Cited by 80 publications

References 28 publications

Fast quantification of proton magnetic resonance spectroscopic imaging with artificial neural networks

Fast quantification of proton magnetic resonance spectroscopic imaging with artificial neural networks

Proton Magnetic Resonance Spectroscopy During Initial Treatment With Antipsychotic Medication in Schizophrenia

MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases

Contact Info

Product

Resources

About